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Abstract
Alzheimer’s disease primarily occurs as sporadic disease and is accompanied with vast socio-economic problems. The
mandatory basic research relies on robust and reliable disease models to overcome increasing incidence and emerging
social challenges. Rodent models are most efficient, versatile, and predominantly used in research. However, only highly
artificial and mostly genetically modified models are available. As these ‘engineered’ models reproduce only isolated
features, researchers demand more suitable models of sporadic neurodegenerative diseases. One very promising animal
model was the South American rodent Octodon degus, which was repeatedly described as natural ‘sporadic Alzheimer’s
disease model’ with ‘Alzheimer’s disease-like neuropathology’. To unveil advantages over the ‘artificial’ mouse models,
we re-evaluated the age-dependent, neurohistological changes in young and aged Octodon degus (1 to 5-years-old)
bred in a wild-type colony in Germany. In our hands, extensive neuropathological analyses of young and aged animals
revealed normal age-related cortical changes without obvious signs for extensive degeneration as seen in patients with
dementia. Neither significant neuronal loss nor enhanced microglial activation were observed in aged animals. Silver
impregnation methods, conventional, and immunohistological stains as well as biochemical fractionations revealed
neither amyloid accumulation nor tangle formation. Phosphoepitope-specific antibodies against tau species displayed
similar intraneuronal reactivity in both, young and aged Octodon degus.
In contrast to previous results, our study suggests that Octodon degus born and bred in captivity do not inevitably
develop cortical amyloidosis, tangle formation or neuronal loss as seen in Alzheimer’s disease patients or transgenic
disease models.
Keywords: Neurodegenerative diseases, Neuropathology, Rodentia, Amyloid beta-Peptides, Tau proteins,
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Introduction
Senile plaques, a hallmark of Alzheimer’s disease (AD),
were long suggested to initiate the destructive cascade to
progressive neuronal dysfunction and death. Nowadays
small, soluble oligomers of β-amyloid (Aβ) are deemed
the primary toxic species [1]. These oligomers disrupt a
variety of receptors [2], increase membrane permeability
[2] and are suspected to induce hyperphosphorylation
and aggregation of tau [3]. Physiologically, Aβ is largely
eliminated from the brain by LRP1 [4] and several ABC
transporters (reviewed in [5, 6]). The vast majority of
cases occur sporadically and a large series of risk factors
have been identified, including age, type 2 diabetes, high
blood pressure, and various genetic factors like specific
alleles of apolipoprotein E (APOE) [7, 8].
A small proportion of AD cases involve genetic variations
which entail alterations in amount, ratio or amino acid se-
quence of Aβ [9]. However, these rare inherited forms are
the fundament of both, disease models and our current un-
derstanding of AD. Due to a lack of alternatives, the main
focus lies on the usage of these genetically manipulated re-
search animals (thus non-sporadic AD models), which re-
stricts the progress of research and limits the scope of
detailed analyses. To successfully combat the sporadic form
of AD, models that develop the disease on a more ‘natural’
basis would certainly help to understand the underlying
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mechanisms which are essential for developing advanced
and efficient therapy options.
The South American rodent Octodon degus (degu) may
be a promising candidate for physiologically modelling
sporadic AD, as it was reported to develop the ‘full range
of AD-like pathologies’ [10] without any genetic manipula-
tion. While wild degus have only a limited life expectancy
(mean: <1 year; common max: 3–4 years), captivity lowers
mortality and increases mean life span to 5–8 years [11]
(Ebensperger L.A. & Hayes L.D., unpublished data). This
captivity-dependent, aged phenotype combined with the
highly homologous Aβ sequence [12], differing only in
one amino acid from human Aβ (see Fig. 1b), might be
the main reasons for their vulnerability. Thus, during the
past years wild-caught and captive born degus were used
in AD research [12–15] and have been referenced in nu-
merous review publications [10, 16–22]. In this course,
prominent intra- and extracellular Aβ deposits were re-
ported in cortical and hippocampal areas of aged animals
(>3 years) [12, 19]. Furthermore, APP and Aβ positive
axonal bulbs were observed in hippocampal white matter
tracts of old animals (6 years) which preceded cerebral
amyloid angiopathy [13]. Biochemical analysis of aged
degus (5-years-old) indicated a correlation between Aβ*56
oligomers and tau phosphorylation on the one hand and
decreased synaptic plasticity and impaired memory per-
formance on the other hand [14]. However, the most
recent study, analysing young (1 to 3 years old) and old
animals (4 to 6 years old), found AD associated autophagy
markers LC3 and p62 unchanged [15]. Furthermore,
GFAP (glial fibrillary acidic protein), CD11b expression,
oxidative stress and apoptosis markers were unaffected in
cortices but elevated in hippocampi of old animals. Cor-
tical and hippocampal levels of AD-linked IL-6 seemed in-
creased in old degus [15].
The aim of the present study was to critically re-
evaluate the suitability of degus as ‘natural’ AD model.
To characterize amyloidosis and tau deposition, different
cortical and hippocampal regions of young (1-year-old)
and aged (5-years-old) wild-type, colony-bred degus
were screened for neurodegenerative changes.
Materials and methods
Drugs and chemicals used in the study were purchased
from Carl Roth, Karlsruhe, Germany; except for those
specifically mentioned.
Animals
Wild-type degus used in the present study were bred at the
Institute of Biology, Otto-von-Guericke-University Magde-
burg. Degus were housed in a climate-controlled environ-
ment (22 °C, 55 ± 5 % humidity) on a 12 h light/dark cycle
with an enriched environment. Social enrichment was pro-
vided by housing in same sex groups of up to 4 animals.
Sensory, motor and cognitive enrichment was provided
by housing the animals in large cages (510x420x680 mm3,
EBECO, Castrop Rauxel, Germany), equipped with a
drinking bottle, burrows for hiding, a running wheel
(Europet-Bernina International, Iserlohn, Germany) for
physical exercise and material for nest building. Nutritional
Fig. 1 Comparison of human and rodent Aβ sequences. Part a shows a simplified phylogenetic tree of rodents. In b, human and rodent sequences of
Aβ42 are compared. The Aβ sequence of guinea pigs (green) equals the human sequence. Chinchillas, degus and naked mole rats (NMRs) share the
same sequence (yellow) with one variation at position 13 as compared to humans. The lesser Egyptian jerboa has an additional difference at position
10 (orange). A larger group of rodents, including mice and rats, show 3 sequential differences at 5, 10 and 13 (red). This sequence is often erroneously
referred to as “rodent Aβ”, as it is the most frequent sequence in rodents. The uniformity of human and degu tau at the analysed phosphorylation
sites is shown in c
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enrichment was provided by providing dry bread, fresh
vegetables and fresh tree branches in addition to the regu-
lar pellet food (rat diet pellets and cereals; ssniff Spezialdiä-
ten, Soest, Germany) ad libitum. A first cohort of degus
was immunohistochemically analysed (J.P.) in two groups:
young (12 months) and aged (60 months), both sexes, at
least two animals per sex and age group. A second cohort
from the same colony was independently analysed in an-
other neuropathological laboratory (C.K.) and used for
quantitative and western blot analyses: seven animals (age
in months: 3, 24, 25, 56, 56, 65, and 65)
Tg-mice, harbouring mutant human amyloid precursor
protein (KM670/671NL) and presenilin 1 (L166P) both
driven by murine Thy1.2-promotor [23], were kindly
provided by the University of Tübingen, Germany. All
mice were housed in a climate-controlled (22 °C) envir-
onment on a 12 h light/dark cycle in same sex groups of
up to 4 animals and free access to food and water. All
experiments were conducted in accordance to the EU
and state law of Saxony-Anhalt and approved by the
local animal ethics committee.
Sequences & alignments
Protein sequences were gathered using NCBI Protein
database (http://www.ncbi.nlm.nih.gov/protein; for ac-
cession numbers see Table 1) and protein alignments
were performed using BLASTP 2.2.30+ [24, 25].
Immunohistochemistry
Animals were sacrificed by cervical dislocation and im-
mediately perfused with 50 mL PBS followed by 50 mL
PFA for fixation. Paraffin-embedded, 4 μm-thick cor-
onal sections were deparaffinised and stained using
Haematoxylin and Eosin. Immunohistochemical ana-
lyses were performed using Bond-Max™ (Leica Micro-
systems, Wetzlar, Germany) automated staining system
as described previously [5, 26–28]. Epitope retrieval
was carried out as follows: 5 min in 95 % (v/v) formic
acid for 6F3D, 4G8 and 6E10; 20 min in EDTA buffer
pH 9.0 for IBA1 and AT180; 10 min enzymatic
digestion (Bond Enzyme Pretreatment Kit, Leica Biosys-
tems Nussloch, Nussloch, Germany) for GFAP or
20 min in citric acid buffer pH 6.0 for NeuN, AT8 and
AT100. Antibodies against ionized calcium-binding
adapter molecule 1 (IBA1 1:1000, 019-19741, Wako
Chemicals, Neuss, Germany), glial fibrillary acid protein
(GFAP, 1:500, Z033401, Dako Deutschland, Hamburg,
Germany), neuronal nuclear antigen (NeuN, 1:500,
MAB377, Merck Chemicals, Darmstadt, Germany)
phosphorylated tau (AT8, 1:50, MN1020; AT100, 1:500,
MN1060; AT180, 1:50, MN1040, Thermo Fisher Scien-
tific, Waltham, MA, USA); β-amyloid (6E10, 1:100,
SIG-39320, Covance Research Products, Denver. PA,
USA; 4G8, 1:2000, SIG-39220, Covance Research Prod-
ucts, Denver. PA, USA; 6F3D, 1:100, M0872, Dako
Deutschland, Hamburg, Germany) were used according
to manufactures instructions. Slides were developed
using Bond™ Polymer Refine Detection kit (Leica
Microsystems, Wetzlar, Germany). For Campbell-
Switzer staining, paraffin-embedded, 4 μm-thick cor-
onal sections were deparaffinised, stirred for 5 min in
ammonium hydroxide and washed twice in distilled
water for 1 min. Sections were incubated for 40 min in
Silver-Pyridine-Carbonate solution (14 % (v/v) pyridine,
0.49 % (w/v) silver nitrate, 0.37 % (w/v) potassium car-
bonate) followed by 3 min in citric acid and washed in
acetate buffer (33.6 mM sodium acetate, 14.4 mM
acetic acid, pH 4.99). Sections were developed in devel-
oper solution (236 mM sodium carbonate, 12.5 mM
ammonium nitrate, 5.9 mM silver nitrate, 1.7 mM
tungstosilicic acid, 0.87 mM formaldehyde) under a
light source for about 6 min. Sections were washed
three times in acetate buffer and once in distilled water,
each for 30 s. Sections were finally placed in 0.5 % (w/
v) sodium thiosulfate solution for 45 s, washed twice in
distilled water and subsequently mounted. Slides were
digitized using MIRAX MIDI Scanner (Carl Zeiss
MicroImaging, Jena, Germany). The scanned slides
were processed using the free Pannoramic Viewer soft-
ware (3DHISTECH, Budapest, Hungary), and analysed
under blinded conditions using either AxioVision (Carl
Zeiss Imaging Solutions; Munich, Germany) or ImageJ
(Wayne Rasband, National Institutes of Health, Bathesda,
MD, USA) and the ITCN plugin (Thomas Kuo and Jiyun
Byun, University of California, CA, USA).
Table 1 Accession numbers of featured proteins from the NCBI
Protein database (http://www.ncbi.nlm.nih.gov/protein/)
Species Accession number
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Four-step fractionation and quantification of Aβ
Animals were sacrificed by cervical dislocation and trans-
cardially perfused with PBS. The brain was immediately
snap-frozen in liquid nitrogen and stored at −80 °C. Frac-
tionation of brain tissue was performed by preparative
ultracentrifugation as described previously [29]. In brief,
brain tissue was homogenated in 9 volumes of TBS buffer
(150 mM sodium chloride, 50 mM Tris, pH 7, supple-
mented with protease inhibitor, Complete EDTA-free,
Roche, Basel, Switzerland) and subsequently centrifuged
(100,000 g, 4 °C, 1 h). The supernatant (TBS-fraction, sol-
uble Aβ) was harvested, pellet was sonicated in 100 μl
TBS/ 1 % (v/v) Triton X-100 and centrifuged again
(100,000 g, 4 °C, 1 h). The supernatant (TX-100-fraction,
detergent soluble Aβ) was harvested, the pellet was soni-
cated in TBS/ 2 % (w/v) SDS and centrifuged (100,000 g,
room temperature, 1 h). Supernatant (SDS-fraction, pro-
tein bound Aβ) was harvested and the remaining pellet
was finally resolved in 70 % formic acid (FA-fraction, in-
soluble Aβ). For quantification, SDS-fraction was diluted
20-fold in TBS and FA-fraction was neutralized with 19
volumes of 1 M Tris (pH 11).
Quantification was performed using the Human/Rat
β-amyloid (40) or (42) ELISA Kit (Wako Chemicals,
Neuss, Germany) according to the manufacturer's in-
structions, which uses BNT77 (epitope: amino acids 11-
16) and BA27 (Aβ40-specific) or BC05 (Aβ42-specific),
respectively [30].
Tau preparation
Brain tissue was mixed with 9 volumes of TBS buffer (sup-
plemented with protease and phosphatase inhibitor,
Sigma-Aldrich, St. Louis, MO, USA), homogenized (total
fraction) and centrifuged (130,000 g, 4 °C, 20 min). The
pellet was resuspended in RIPA buffer (150 mM sodium
chloride, 50 mM Tris, 0.5 % (w/v) deoxycholic acid, 1 %
(v/v) Triton X-100, 0.5 % (w/v) SDS, 25 mM EDTA, pH 8
supplemented with protease and phosphatase inhibitor)
and centrifuged again (130,000 g, 4 °C, 20 min). Super-
natant was discarded; pellet was resuspended in 70 %
formic acid and centrifuged (130,000 g, 4 °C, 20 min).
Supernatant (FA-fraction) was neutralized with two vol-
umes of neutralization buffer (5 M sodium hydroxide,
0.5 M Tris, 0.25 M monosodium phosphate). Proteins
were precipitated using 2,2,2-trichloroacetic acid (25 % (v/
v) TCA) for 30 min at 4 °C and subsequently separated by
centrifugation (22,000 g, 4 °C, 15 min). Resulting pellet
(insoluble fraction) was washed two times with cold acet-
one and subsequently air-dried.
Western blot
Total and insoluble fractions were separated on a redu-
cing 4–12 % Bis-Tris gel (Thermo Fisher Scientific,
Waltham, MA, USA) and subsequently transferred to
nitrocellulose membrane. Phosphorylated tau was de-
tected using AT8 (1:1,000, MN1020, Thermo Fisher Sci-
entific, Waltham, MA, USA) and total tau levels using
HT7 antibody (1:1,000, MN1000, Thermo Fisher Scien-
tific, Waltham, MA, USA), and protein expression was
normalized with internal control anti-actin (1:10,000,
Sigma-Aldrich, St. Louis, MO, USA).
Statistics
For all quantifications, animals of either sex were used
(n ≥ 2 per sex; n ≥ 4 per group), statistical significance
(p ≤ 0.05) was determined using unpaired t-tests with
Welch’s correction (Prism 6, GraphPad Software La
Jolla, CA, USA).
Results
Routine histological Haematoxylin and Eosin (H&E) stains
of young (1 year) and old (5 years) wild-type degus re-
vealed normal age-related changes in the examined brain
regions, but no obvious signs for specific lesions, neurode-
generation, or neuronal displacement (Fig. 2a, b).
Neuronal marker NeuN unveiled no generalized loss of
cortical neurons between both time points (Fig. 2c, d, m).
Microglia-specific stains of ionized calcium-binding
adapter molecule 1 (IBA1), which can unravel early signs
of pathology shown by localised microglia accumulation,
displayed homogenously distributed populations of resting
microglia in young and aged animals (Fig. 2e, f ). Individual
differences in young and aged degus were apparent, but
the cortical coverage was not significantly different be-
tween the two groups (Fig. 2n). Cortical clustering of
microglia as seen in pre-depositing APP-transgenic mice,
pinpointing towards starting Aβ deposition, was not de-
tected. Cortical astroglia (GFAP-positive) were nearly ex-
clusively located in cortical layer 1 and around blood
vessels (Fig. 2g, h, o), without any age-dependent changes
in spatial distribution or intensity.
To evaluate the extent of any cortical amyloidosis and
neuronal destruction, a modified Campbell-Switzer stain
was applied, but no extracellular deposits were exposed
(Fig. 2i, j). This result was supported by thioflavin T
stains which revealed no specific cortical fluorescence as
well (Fig. 2k, l).
To examine potentially undiscovered amyloid
deposits, we performed more sensitive immunohisto-
chemical stains by employing commonly used anti-
bodies against different Aβ epitopes (clones 6F3D,
4G8, 6E10). The epitope of clone 6E10 is located N-
terminal of the H13R substitution (within amino acids
3-8). Besides high unspecific background staining,
limited intracellular immunoreactivity was detected in
all cortices of young and aged degus. However, extra-
cellular deposits (e.g. plaques) could not be traced in
any of the examined brain regions (Fig. 3a, b). The
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epitope of anti-Aβ antibody clone 6F3D (amino acids
8-17) includes the H13R substitution and showed nei-
ther intra- nor extracellular immunoreactivity in
young or aged animals (Fig. 3c, d). Likewise, no ag-
gregates could be detected using the 4G8 antibody
(Fig. 3e, f ) with an epitope C-terminally of the H13R
substitution (amino acids: 18-22). The lack of age-
dependent, immunohistological changes in degus was
independently confirmed by a second neuropatho-
logical laboratory (C.K.) in an additional study (1 to
5 year old degus from the same colony, anti-amyloid
stains using clones 6E10 and IC16; data not shown).
Levels of cortical and hippocampal Aβ40 and Aβ42
in young and aged degus were quantitatively
measured using immunoassays (Fig. 4), revealing very
low levels of soluble and membrane-bound Aβ and
low levels of protein-bound and insoluble Aβ. The
levels of insoluble Aβ did not age-dependently
change. However, the concentration of insoluble Aβ
was generally several magnitudes below those of
established AD mouse models, and even lower than
those of wild-type naked mole rats and guinea pigs
(Table 2). The comparison of wild-type degus, wild-
type and transgenic mice demonstrates that aged
wild-type degus very closely resemble histological pa-
rameters of wild-type mice in terms of Aβ deposition
and unspecific activation of microglial and astroglial
cells (Fig. 5).
Fig. 2 Immunohistochemical analysis of young and aged degus. H&E stain revealed normal age-related changes but no signs for lesions,
neurodegeneration, or displacement in young (1-year-old, a) and aged (5-years-old, b) animals. Density of cortical neurons (NeuN-satin) remained
virtually unchanged in aged degus (d), compared to young (c). IBA1-stain (e, f) revealed homologues populations of resting microglia cells
(young, e; aged, f)). GFAP Immunoreactivity was slightly decreased in aged animals (h), but spatial distribution (layer 1, surrounding vessels) was
similar (young: g; aged: h). Campbell-Switzer stain unveiled neither extracellular plaques nor tangles (i, j). Thioflavin T likewise indicated no
amyloid plaques (young, k; aged, l). Semi-automatically determination of neurons (m) as well as microglial cells (n) and astrocytes (o) in cortices
revealed no significant changes in aged animals. Scale bars = 100 μm. Data is presented as mean ± SEM (n≥ 4)
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Phosphorylated tau is the second protein accumulating
during disease progression and another histopathological
hallmark of AD [31]. We utilized antibodies against differ-
ent epitopes of phosphorylated tau to screen for neurofibril-
lary tangles. Although sequences of human and degu tau
vary, the analysed phosphorylation sites (Ser202/Thr205,
Thr212/Ser214 and Thr231) are identical (Fig. 1c). AT8
(Ser202/Thr205) labelled cortical neurons in young and
aged animals (Fig. 6a, b) and AT100 (Thr212/Ser214)
showed nuclear-localized reactivity (Fig. 6c, d). AT100 epi-
tope is known for nuclear co-localization and considered
not tau-specific, as it appears likewise in tau knockout mice
[32]. AT180 (Thr231) equally stained cortical neurons of
young and aged degus (Fig. 6e, f). In sum, the detected tau
did morphologically not correspond to neurofibrillary
tangles and showed no age-dependent intensification.
Fig. 3 β-amyloid pathology in young and aged degus. Aβ staining using 6E10-antibody (a, b) resulted in unspecific background signals accompanied
by spot-like intracellular immunoreactivity. Although visible in both, young (a) and aged (b), intensity generally tends to be elevated in aged animals.
In contrast, no immunoreactivity was detected in young (c, e) or aged (d, f) degus using 6F3D (c, d), or 4G8 (e, f). Scale bar = 100 μm
Fig. 4 Aβ levels in fractionated brain tissue of young and aged degus. Levels of Aβ40 and Aβ42 were measured in fractionated cortical (black) and
hippocampal (grey) tissue of young (a, c) and aged (b, d) degus using immunoassays. a, b In both groups, Aβ40 was rarely present in soluble (TBS) and
membrane-bound (TX-100) forms. The highest amounts were protein-bound (SDS) and smaller proportions were insoluble (formic acid; FA). Overall,
young and aged animals demonstrated very similar levels Aβ40. c, d Young and aged degus showed low levels of Aβ42 in soluble (TBS) and
membrane-bound (TX-100) fractions and higher levels in protein-bound (SDS) and insoluble (FA) fractions in both, cortex and hippocampus. Aβ42
levels were likewise not crucially changed in aged animals. Data is presented as mean ± SEM (young: 3, 24 months; aged: 56, 56, 65, 65 months)
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Moreover, the independent quantification of tau
revealed neither elevated levels of total tau, nor an in-
crease in phosphorylated or insoluble fraction (Fig. 7).
Discussion
In the near future, aging societies will be particu-
larly challenged by age-related diseases demanding
intensive care. Exceptional research endeavours are
necessary to face these approaching challenges. Thus,
reliable and accurate animal models are one of the
major prerequisites in basic research. Although trans-
genic rodent models of AD are constantly refined, no
model yet mimics all pathological features of this
complex disease. More accurate models maintaining
Table 2 Levels of insoluble Aβ in transgenic AD models and wild-type rodents
Model Age (months) Aβ40 (pg/mg) Aβ42 (pg/mg) Reference
AD models APP23 12 3098 746 [54]
APPLondon 24 1300 3300 [55]
Tg2576 2–3 700 2100 [56]
>20 39,900 40,900 [57]
APP/PS1 5 26,200 49,400 [58]
8 166,000 113,500
Wild-type naked mole rats 2–9 years 37 60 [34]
Guinea pig adult 79 18 [59]
Fig. 5 Comparison of neuropathological changes in wild-type degus, wild-type and transgenic mice. While aged wild-type degus (a, 5 years old) and
mice (b, 200-days-old) exhibit no sign of β-amyloid deposition, APP/PS1 transgenic mice present with obvious cortical amyloidosis (c, 150-days-old).
Compared to wild-type degus (d, g) and mice (e, h), transgenic mice manifest with pronounced micro- (f) and astrogliosis (i). Scale bars = 200 μm
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the beneficial characteristics of rodents would lead to
a better understanding and more expedient thera-
peutic approaches. Degus were described as a promis-
ing natural model of Alzheimer’s disease during the
last years by a Chilean group. However, in our studies
we were unable to detect any systematic occurrence
of the typical histopathological hallmarks of AD in re-
lation to age. Haematoxylin and Eosin as well as
NeuN stains showed not more than slight differences
between young and aged degus, rather indicative for
the natural aging process than pathological neurode-
generation. In contrast to previous results from Ines-
trosa et al. [15], we could not detect elevated GFAP
expression in old degus compared to young animals.
The lack of signs for microglial and astrocytic inflam-
mation further reiterates the absence of a pathological
degeneration in the examined brains of the old degus.
Aβ pathology
The sparse intracellular reactivity of anti-Aβ clone 6E10,
which was lacking in clone 4G8, clone 6F3D, Campbell-
Switzer and thioflavin T stains, most likely indicates an
unspecific reaction [33]. In contrast, no sign of any
extracellular deposition of Aβ was detected in aged ani-
mals by any of the applied staining methods (Fig. 3).
Quantitative measurements underpinned the absence of
considerable amounts of insoluble Aβ (Fig. 4) and re-
vealed Aβ-levels that are in the same range as those in
wild-type mice [29] and below those of wild-type naked
mole rats [34].
Consistent with results of van Groen et al. no signifi-
cant neuronal loss was found in the brain of 5-years-old
degus [13]. These findings are in sharp contrast to ob-
servations in brains of degus obtained from their natural
habitat, in which prominent intra- and extracellular Aβ
deposits in cortices and hippocampi of aged animals
(>3 years) were reported [12, 19]. These differences may,
at least in part, be caused by different rearing conditions
(laboratory housing versus natural wildlife conditions)
and it has to be considered that in their wildlife habitat
the animals are exposed to stress, may suffer from
hypertension, viral infections and diabetes, i.e. known
risk factors contributing to the aetiology of AD and the
early development of AD-type neuropathology.
Furthermore, the single amino-acid-difference between
degus and humans at position 13 (histidine to arginine)
affects a histidine residue (His13) which is crucial for
aggregation and toxicity of Aβ. His13 is involved in early
N-terminal β-sheet formation [35] and a substitution
lowers aggregation propensity [36], neuronal binding [37],
and cytotoxicity [36]. Moreover, His13 is involved in the
coordination of metal ions [38] and methylation or
Fig. 6 Tau pathology in young and aged degus. Phosphoepitope-specific antibodies were used to examine involvement of tau. AT8 revealed
intracellular immunoreactivity in young and aged degus (a, b). AT100 was unspecific and appeared almost entirely in the nucleus (c, d). AT180-
labelled cortical neurons in young and aged animals (e, f). Scale bar = 100 μm
Fig. 7 Total and insoluble levels of cortical tau in young and aged
degus. Biochemical analysis of total and insoluble tau in cortices of
young and aged degus revealed high individual variance, but no
significant age-related changes in levels of neither total (HT7) nor
phosphorylated (AT8) tau. β-actin served as loading control. Age of
degus (left to right in months): 3, 24, 25, 56, 56, 65, 65
Steffen et al. Acta Neuropathologica Communications  (2016) 4:91 Page 8 of 11
substitution by arginine, as seen in degus, lowers the affin-
ity for metal ions and thus depletes aggregation [38–40]
and attenuates toxicity [41, 42] of Aβ.
Two other species which are related to degus share a
similar Aβ sequence, but, despite higher life expectancies,
lack the neuropathological features as reported for degus.
Naked mole rats (Heterocephalus glaber) have the identi-
cal Aβ sequence (see Fig. 1) and an exceptional lifespan of
more than 30 years [34]. Although young naked mole rats
naturally exhibit pronounced oxidative stress [43] and Aβ
levels similar to 3xTg-AD mice [34, 43], they do not de-
velop amyloid plaques with age [34]. Furthermore, naked
mole rats even present with high levels of phosphorylated
tau without any tangle formation [44]. In Guinea pigs
(Cavia porcellus), with a human identical Aβ sequence
(see Fig. 1) and a lifespan similar to degus (average 5–7
[45]), dense amyloid deposits do not occur [45], despite
similar APP processing [46, 47] and high β–secretase
activity [47].
Tau pathology
The additional screening for tau deposition, the second
aggregating protein in AD, revealed similar intracellular
reactivity in young and aged degus using phosphoepitope-
specific antibodies AT8 and AT180. AT100 staining
showed the previously described, unspecific nuclear
localization [32]. Biochemical analysis did not reveal an
age-dependent increase of total, insoluble or phosphory-
lated tau (Fig. 7). Some variability observed in the levels of
total tau or insoluble tau could hint subsets with different
aggregation propensities but the very same animals did
not exhibit tau pathology in IHC, and larger number of
animals would be needed to identify the existence of such
subsets. Hence, no evidence for a pathological deposition
of tau could be detected in the examined animals.
Methodological considerations
The animals used in a variety of studies were collected
from different sources [13, 48, 49], including animals
caught in the wild [12, 50], the latter does usually not
allow a precise age determination and thus hinders pre-
cisely controlled analyses. However, standardised hous-
ing conditions as used for the degus examined in the
present study seem to prevent the development of ‘AD-
like’ pathology described for wild-caught animals. None-
theless, it would be fascinating to decipher the factors
inducing the histopathological and biochemical changes
in degus previously described [12, 13, 15]. Moreover, not
only the particular species or the specific amino acid se-
quence seems influence the extent of amyloid depos-
ition, but the genetic background likewise enfolds a
strong effect [26]. As degus are not yet an established re-
search model, they lack a defined, stable and character-
ized inbred genetic background.
An interesting approach of separating old degus with
severely aberrant behaviour as disease model takes high
individual variability into account and indicates that
‘AD-like’ pathology might not necessarily develop in old
degus. However, even in this selected subgroup with in-
creased levels of inflammatory and oxidative stress
markers, no correlation between altered behaviour and
specific neuropathological symptoms could be estab-
lished [50]. The stated impairments of spatial memory
and cognition in aged degus [14] may therefore be just a
part of the normal aging process, since physiologic aging
is linked to significant impairments in memory [51],
cognition [52] and hippocampal long-term potentiation
[53] in mice as well. Thus, symptoms of normal aging
may not be misinterpreted to model AD.
Conclusion
Octodon degus was re-evaluated in the context of exist-
ing rodent AD models and human AD pathology. Per-
forming immunohistological and molecular analyses of
young and aged animals, we were able to show exclu-
sively normal age-related cortical changes without indi-
cations for extensive degeneration as seen in patients
with dementia and transgenic AD mice. Neither signifi-
cant neuronal loss nor enhanced microglial activation
were observed in aged animals of our degu population.
Furthermore, no amyloid accumulation or tangle forma-
tion as seen in sporadic Alzheimer’s disease patients
could be determined. Phosphoepitope-specific antibodies
against tau species displayed similar intracellular neur-
onal reactivity in both, young and aged degus.
Moreover, we highlighted some previous results, which
stand in contrast to the assumption of degus as natural
AD model and seem to be thus far neglected. Bearing that
in mind, assessment of degus as AD models should be
meticulously done and receive particular attention. Cur-
rently, it is not clear if unnoticed environmental or rearing
factors might play a role in triggering AD-like neuropath-
ology. Therefore, we conclude that presently, the rodent
Octodon degus is neither a superior model which is more
suitable than other frequently used rodent models nor a
‘natural’ model of Alzheimer’s disease in general.
Acknowledgements
The work was financed by the following grants to J.P. (Deutsche
Forschungsgemeinschaft DFG PA930/9, DFG PA930/12; VIAA Latvia NFI/R/
2014/023; Leibniz Society SAW-2015-IPB-2; HelseSØ No:2016062; Norsk for-
skningsrådet: NFR251290, NFR246392, NFR248772, JPND NeuroGEM
NFR247179, JPND PROP-AD NFR260786), K.B. (German-Israeli Foundation for
Scientific Research and Development (GIF), BMBF Grants UBICA, TRANS-GEN).
and C.K. (BMBF #01GQ1422A EU-FP7 MC-ITN IN-SENS #607616).
Authors’ contributions
JS, MK, KP, CS conducted investigations, wrote manuscript; TB conducted
investigations; RM, AMS, CK: conducted experiments, wrote manuscript; KB
provided O. degu cohort, wrote manuscript; JP planned study, conducted
investigations, wrote manuscript. All authors read and approved the final
manuscript.
Steffen et al. Acta Neuropathologica Communications  (2016) 4:91 Page 9 of 11
Competing interests
The authors declare that they have no competing interests.
Author details
1University of Lübeck (UzL), LIED, Lübeck, Germany. 2Department of Neuro-/
Pathology, University of Oslo (UiO) & Oslo University Hospital (OUS), Oslo,
Norway. 3Department of Neuropathology, Heinrich Heine University
Düsseldorf (HHU), Düsseldorf, Germany. 4Department of Zoology/
Developmental Neurobiology, Otto von Guericke University Magdeburg
(OvGU), Magdeburg, Germany. 5Leibniz Institute for Plant Biochemistry (IPB),
Halle, Germany. 6Department of Pathology (PAT), Translational
Neurodegeneration Research and Neuropathology Lab, University of Oslo,
Postboks 4950, Nydalen 0424, Oslo, Norway.
Received: 11 August 2016 Accepted: 11 August 2016
References
1. Glabe CG. Common mechanisms of amyloid oligomer pathogenesis in
degenerative disease. Neurobiol Aging. 2006;27(4):570–5. doi:10.1016/j.
neurobiolaging.2005.04.017.
2. Kayed R, Lasagna-Reeves CA. Molecular mechanisms of amyloid oligomers
toxicity. J Alzheimers Dis. 2013;33 Suppl 1:S67–78. doi:10.3233/JAD-2012-
129001.
3. Choi SH, Kim YH, Hebisch M, Sliwinski C, Lee S, D'Avanzo C, Chen H, Hooli
B, Asselin C, Muffat J, Klee JB, Zhang C, Wainger BJ, Peitz M, Kovacs DM,
Woolf CJ, Wagner SL, Tanzi RE, Kim DY. A three-dimensional human neural
cell culture model of Alzheimer's disease. Nature. 2014;515(7526):274–8. doi:
10.1038/nature13800.
4. Pflanzner T, Janko MC, Andre-Dohmen B, Reuss S, Weggen S, Roebroek AJ,
Kuhlmann CR, Pietrzik CU. LRP1 mediates bidirectional transcytosis of
amyloid-beta across the blood-brain barrier. Neurobiol Aging. 2011;32(12):
2323. 10.1016/j.neurobiolaging.2010.05.025.
5. Krohn M, Lange C, Hofrichter J, Scheffler K, Stenzel J, Steffen J, Schumacher
T, Bruning T, Plath AS, Alfen F, Schmidt A, Winter F, Rateitschak K, Wree A,
Gsponer J, Walker LC, Pahnke J. Cerebral amyloid-beta proteostasis is
regulated by the membrane transport protein ABCC1 in mice. J Clin Invest.
2011;121(10):3924–31. doi:10.1172/JCI57867.
6. Pahnke J, Frohlich C, Paarmann K, Krohn M, Bogdanovic N, Arsland D,
Winblad B. Cerebral ABC transporter-common mechanisms may modulate
neurodegenerative diseases and depression in elderly subjects. Arch Med
Res. 2014;45(8):738–43. doi:10.1016/j.arcmed.2014.10.010.
7. Reitz C, Mayeux R. Alzheimer disease: epidemiology, diagnostic criteria, risk
factors and biomarkers. Biochem Pharmacol. 2014;88(4):640–51. doi:10.1016/
j.bcp.2013.12.024.
8. Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo MM,
Abraham R, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Jones N, Stretton A,
Thomas C, Richards A, Ivanov D, Widdowson C, Chapman J, Lovestone S, Powell
J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Brown
KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD,
Beaumont H, Warden D, Wilcock G, Love S, Kehoe PG, Hooper NM, Vardy ER,
Hardy J, Mead S, Fox NC, Rossor M, Collinge J, Maier W, Jessen F, Ruther E,
Schurmann B, Heun R, Kolsch H, van den Bussche H, Heuser I, Kornhuber J,
Wiltfang J, Dichgans M, Frolich L, Hampel H, Gallacher J, Hull M, Rujescu D,
Giegling I, Goate AM, Kauwe JS, Cruchaga C, Nowotny P, Morris JC, Mayo K,
Sleegers K, Bettens K, Engelborghs S, De Deyn PP, Van Broeckhoven C, Livingston
G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Al-Chalabi A, Shaw CE,
Tsolaki M, Singleton AB, Guerreiro R, Muhleisen TW, Nothen MM, Moebus S,
Jockel KH, Klopp N, Wichmann HE, Pankratz VS, Sando SB, Aasly JO, Barcikowska
M, Wszolek ZK, Dickson DW, Graff-Radford NR, Petersen RC, Alzheimer's Disease
Neuroimaging I, van Duijn CM, Breteler MM, Ikram MA, DeStefano AL, Fitzpatrick
AL, Lopez O, Launer LJ, Seshadri S, Consortium C, Berr C, Campion D, Epelbaum
J, Dartigues JF, Tzourio C, Alperovitch A, Lathrop M, Consortium E, Feulner TM,
Friedrich P, Riehle C, Krawczak M, Schreiber S, Mayhaus M, Nicolhaus S,
Wagenpfeil S, Steinberg S, Stefansson H, Stefansson K, Snaedal J, Bjornsson S,
Jonsson PV, Chouraki V, Genier-Boley B, Hiltunen M, Soininen H, Combarros O,
Zelenika D, Delepine M, Bullido MJ, Pasquier F, Mateo I, Frank-Garcia A, Porcellini
E, Hanon O, Coto E, Alvarez V, Bosco P, Siciliano G, Mancuso M, Panza F, Solfrizzi
V, Nacmias B, Sorbi S, Bossu P, Piccardi P, Arosio B, Annoni G, Seripa D, Pilotto A,
Scarpini E, Galimberti D, Brice A, Hannequin D, Licastro F, Jones L, Holmans PA,
Jonsson T, Riemenschneider M, Morgan K, Younkin SG, Owen MJ, O'Donovan M,
Amouyel P, Williams J. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1,
CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet. 2011;43(5):
429–35. doi:10.1038/ng.803.
9. Schellenberg GD, Montine TJ. The genetics and neuropathology of
Alzheimer's disease. Acta Neuropathol. 2012;124(3):305–23. doi:10.1007/
s00401-012-0996-2.
10. Braidy N, Munoz P, Palacios AG, Castellano-Gonzalez G, Inestrosa NC, Chung
RS, Sachdev P, Guillemin GJ. Recent rodent models for Alzheimer's disease:
clinical implications and basic research. J Neural Transm (Vienna). 2012;
119(2):173–95. doi:10.1007/s00702-011-0731-5.
11. Ebensperger LA, Tapia D, Ramirez-Estrada J, Leon C, Soto-Gamboa M, Hayes
LD. Fecal cortisol levels predict breeding but not survival of females in the
short-lived rodent, Octodon degus. Gen Comp Endocrinol. 2013;186:164–71.
doi:10.1016/j.ygcen.2013.02.044.
12. Inestrosa NC, Reyes AE, Chacon MA, Cerpa W, Villalon A, Montiel J, Merabachvili
G, Aldunate R, Bozinovic F, Aboitiz F. Human-like rodent amyloid-beta-peptide
determines Alzheimer pathology in aged wild-type Octodon degu. Neurobiol
Aging. 2005;26(7):1023–8. doi:10.1016/j.neurobiolaging.2004.09.016.
13. van Groen T, Kadish I, Popovic N, Popovic M, Caballero-Bleda M, Bano-Otalora
B, Vivanco P, Rol MA, Madrid JA. Age-related brain pathology in Octodon
degu: blood vessel, white matter and Alzheimer-like pathology. Neurobiol
Aging. 2011;32(9):1651–61. doi:10.1016/j.neurobiolaging.2009.10.008.
14. Ardiles AO, Tapia-Rojas CC, Mandal M, Alexandre F, Kirkwood A, Inestrosa NC,
Palacios AG. Postsynaptic dysfunction is associated with spatial and object
recognition memory loss in a natural model of Alzheimer's disease. Proc Natl
Acad Sci U S A. 2012;109(34):13835–40. doi:10.1073/pnas.1201209109.
15. Inestrosa NC, Rios JA, Cisternas P, Tapia-Rojas C, Rivera DS, Braidy N, Zolezzi
JM, Godoy JA, Carvajal FJ, Ardiles AO, Bozinovic F, Palacios AG, Sachdev PS.
Age Progression of Neuropathological Markers in the Brain of the Chilean
Rodent Octodon degus, a Natural Model of Alzheimer's Disease. Brain
Pathol. 2015;25(6):679–91. doi:10.1111/bpa.12226.
16. Ardiles AO, Ewer J, Acosta ML, Kirkwood A, Martinez AD, Ebensperger LA,
Bozinovic F, Lee TM, Palacios AG. Octodon degus (Molina 1782): a model in
comparative biology and biomedicine. Cold Spring Harb Protoc. 2013;
2013(4):312–8. doi:10.1101/pdb.emo071357.
17. Tarragon E, Lopez D, Estrada C, Ana GC, Schenker E, Pifferi F, Bordet R,
Richardson JC, Herrero MT. Octodon degus: a model for the cognitive
impairment associated with Alzheimer's disease. CNS Neurosci Ther. 2013;
19(9):643–8. doi:10.1111/cns.12125.
18. Iqbal K, Bolognin S, Wang X, Basurto-Islas G, Blanchard J, Tung YC. Animal models
of the sporadic form of Alzheimer's disease: focus on the disease and not just the
lesions. J Alzheimers Dis. 2013;37(3):469–74. doi:10.3233/JAD-130827.
19. Rios JA, Cisternas P, Arrese M, Barja S, Inestrosa NC. Is Alzheimer's disease
related to metabolic syndrome? A Wnt signaling conundrum. Prog
Neurobiol. 2014;121:125–46. doi:10.1016/j.pneurobio.2014.07.004.
20. Castro-Fuentes R, Socas-Perez R. Octodon degus: a strong attractor for
Alzheimer research. Basic Clin Neurosci. 2013;4(1):91–6.
21. Braidy N, Poljak A, Jayasena T, Mansour H, Inestrosa NC, Sachdev PS.
Accelerating Alzheimer's research through 'natural' animal models. Curr
Opin Psychiatry. 2015;28(2):155–64. doi:10.1097/YCO.0000000000000137.
22. Rivera DS, Inestrosa NC, Bozinovic F. On cognitive ecology and the
environmental factors that promote Alzheimer disease: lessons from
Octodon degus (Rodentia: Octodontidae). Biol Res. 2016;49:10. doi:10.
1186/s40659-016-0074-7.
23. Radde R, Bolmont T, Kaeser SA, Coomaraswamy J, Lindau D, Stoltze L,
Calhoun ME, Jaggi F, Wolburg H, Gengler S, Haass C, Ghetti B, Czech C,
Holscher C, Mathews PM, Jucker M. Abeta42-driven cerebral amyloidosis in
transgenic mice reveals early and robust pathology. EMBO Rep. 2006;7(9):
940–6. doi:10.1038/sj.embor.7400784.
24. Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller W, Lipman DJ.
Gapped BLAST and PSI-BLAST: a new generation of protein database search
programs. Nucleic Acids Res. 1997;25(17):3389–402.
25. Altschul SF, Wootton JC, Gertz EM, Agarwala R, Morgulis A, Schaffer AA, Yu
YK. Protein database searches using compositionally adjusted substitution
matrices. FEBS J. 2005;272(20):5101–9. doi:10.1111/j.1742-4658.2005.04945.x.
26. Frohlich C, Paarmann K, Steffen J, Stenzel J, Krohn M, Heinze HJ, Pahnke J.
Genomic background-related activation of microglia and reduced beta-
amyloidosis in a mouse model of Alzheimer's disease. Eur J Microbiol
Immunol (Bp). 2013;3(1):21–7. doi:10.1556/EuJMI.3.2013.1.3.
27. Schumacher T, Krohn M, Hofrichter J, Lange C, Stenzel J, Steffen J,
Dunkelmann T, Paarmann K, Frohlich C, Uecker A, Plath AS, Sommer A,
Steffen et al. Acta Neuropathologica Communications  (2016) 4:91 Page 10 of 11
Bruning T, Heinze HJ, Pahnke J. ABC transporters B1, C1 and G2 differentially
regulate neuroregeneration in mice. PLoS One. 2012;7(4):e35613. doi:10.
1371/journal.pone.0035613.
28. Frohlich C, Zschiebsch K, Groger V, Paarmann K, Steffen J, Thurm C, Schropp
EM, Bruning T, Gellerich F, Radloff M, Schwabe R, Lachmann I, Krohn M,
Ibrahim S, Pahnke J. Activation of Mitochondrial Complex II-Dependent
Respiration Is Beneficial for alpha-Synucleinopathies. Mol Neurobiol. 2016;
53(7):4728–44. doi:10.1007/s12035-015-9399-4.
29. Muller-Schiffmann A, Herring A, Abdel-Hafiz L, Chepkova AN, Schable S,
Wedel D, Horn AH, Sticht H, de Souza Silva MA, Gottmann K, Sergeeva OA,
Huston JP, Keyvani K, Korth C. Amyloid-beta dimers in the absence of
plaque pathology impair learning and synaptic plasticity. Brain. 2016;139(Pt
2):509–25. doi:10.1093/brain/awv355.
30. Oshima N, Morishima-Kawashima M, Yamaguchi H, Yoshimura M,
Sugihara S, Khan K, Games D, Schenk D, Ihara Y. Accumulation of
amyloid beta-protein in the low-density membrane domain accurately
reflects the extent of beta-amyloid deposition in the brain. Am J
Pathol. 2001;158(6):2209–18.
31. Grundke-Iqbal I, Iqbal K, Quinlan M, Tung YC, Zaidi MS, Wisniewski HM.
Microtubule-associated protein tau. A component of Alzheimer paired
helical filaments. J Biol Chem. 1986;261(13):6084–9.
32. Whiteman IT, Minamide LS, de Goh L, Bamburg JR, Goldsbury C. Rapid
changes in phospho-MAP/tau epitopes during neuronal stress: cofilin-actin
rods primarily recruit microtubule binding domain epitopes. PLoS One.
2011;6(6):e20878. doi:10.1371/journal.pone.0020878.
33. Aho L, Pikkarainen M, Hiltunen M, Leinonen V, Alafuzoff I. Immunohistochemical
visualization of amyloid-beta protein precursor and amyloid-beta in extra- and
intracellular compartments in the human brain. J Alzheimers Dis. 2010;20(4):
1015–28. doi:10.3233/JAD-2010-091681.
34. Edrey YH, Medina DX, Gaczynska M, Osmulski PA, Oddo S, Caccamo A,
Buffenstein R. Amyloid beta and the longest-lived rodent: the naked mole-
rat as a model for natural protection from Alzheimer's disease. Neurobiol
Aging. 2013;34(10):2352–60. doi:10.1016/j.neurobiolaging.2013.03.032.
35. Dong X, Chen W, Mousseau N, Derreumaux P. Energy landscapes of the
monomer and dimer of the Alzheimer's peptide Abeta(1-28). J Chem Phys.
2008;128(12):125108. doi:10.1063/1.2890033.
36. Dai X, Sun Y, Gao Z, Jiang Z. Copper enhances amyloid-beta peptide
neurotoxicity and non beta-aggregation: a series of experiments conducted
upon copper-bound and copper-free amyloid-beta peptide. J Mol Neurosci.
2010;41(1):66–73. doi:10.1007/s12031-009-9282-8.
37. Poduslo JF, Howell KG, Olson NC, Ramirez-Alvarado M, Kandimalla KK.
Alzheimer's disease amyloid beta-protein mutations and deletions that
define neuronal binding/internalization as early stage nonfibrillar/fibrillar
aggregates and late stage fibrils. Biochemistry. 2012;51(19):3993–4003. doi:
10.1021/bi300275g.
38. Liu ST, Howlett G, Barrow CJ. Histidine-13 is a crucial residue in the zinc ion-
induced aggregation of the A beta peptide of Alzheimer's disease.
Biochemistry. 1999;38(29):9373–8. doi:10.1021/bi990205o.
39. Huang J, Yao Y, Lin J, Ye YH, Sun WY, Tang Dagger WX. The solution
structure of rat Abeta-(1-28) and its interaction with zinc ion: insights into
the scarcity of amyloid deposition in aged rat brain. J Biol Inorg Chem.
2004;9(5):627–35. doi:10.1007/s00775-004-0556-x.
40. Miura T, Suzuki K, Kohata N, Takeuchi H. Metal binding modes of
Alzheimer's amyloid beta-peptide in insoluble aggregates and soluble
complexes. Biochemistry. 2000;39(23):7024–31.
41. Smith DP, Smith DG, Curtain CC, Boas JF, Pilbrow JR, Ciccotosto GD, Lau TL,
Tew DJ, Perez K, Wade JD, Bush AI, Drew SC, Separovic F, Masters CL,
Cappai R, Barnham KJ. Copper-mediated amyloid-beta toxicity is associated
with an intermolecular histidine bridge. J Biol Chem. 2006;281(22):15145–54.
doi:10.1074/jbc.M600417200.
42. Tickler AK, Smith DG, Ciccotosto GD, Tew DJ, Curtain CC, Carrington D,
Masters CL, Bush AI, Cherny RA, Cappai R, Wade JD, Barnham KJ.
Methylation of the imidazole side chains of the Alzheimer disease amyloid-
beta peptide results in abolition of superoxide dismutase-like structures and
inhibition of neurotoxicity. J Biol Chem. 2005;280(14):13355–63. doi:10.1074/
jbc.M414178200.
43. Edrey YH, Oddo S, Cornelius C, Caccamo A, Calabrese V, Buffenstein R.
Oxidative damage and amyloid-beta metabolism in brain regions of the
longest-lived rodents. J Neurosci Res. 2014;92(2):195–205. doi:10.1002/jnr.23320.
44. Orr ME, Garbarino VR, Salinas A, Buffenstein R. Sustained high levels of
neuroprotective, high molecular weight, phosphorylated tau in the
longest-lived rodent. Neurobiol Aging. 2015;36(3):1496–504. doi:10.1016/
j.neurobiolaging.2014.12.004.
45. Bates K, Vink R, Martins R, Harvey A. Aging, cortical injury and Alzheimer's
disease-like pathology in the guinea pig brain. Neurobiol Aging. 2014;35(6):
1345–51. doi:10.1016/j.neurobiolaging.2013.11.020.
46. Beck M, Bruckner MK, Holzer M, Kaap S, Pannicke T, Arendt T, Bigl V. Guinea-pig
primary cell cultures provide a model to study expression and amyloidogenic
processing of endogenous amyloid precursor protein. Neuroscience. 2000;
95(1):243–54.
47. Beck M, Bigl V, Rossner S. Guinea pigs as a nontransgenic model for APP
processing in vitro and in vivo. Neurochem Res. 2003;28(3-4):637–44.
48. Palacios-Munoz A, Escobar MJ, Vielma A, Araya J, Astudillo A, Valdivia G,
Garcia IE, Hurtado J, Schmachtenberg O, Martinez AD, Palacios AG. Role of
connexin channels in the retinal light response of a diurnal rodent. Front
Cell Neurosci. 2014;8:249. doi:10.3389/fncel.2014.00249.
49. Kumazawa-Manita N, Katayama M, Hashikawa T, Iriki A. Three-
dimensional reconstruction of brain structures of the rodent Octodon
degus: a brain atlas constructed by combining histological and
magnetic resonance images. Exp Brain Res. 2013;231(1):65–74. doi:10.
1007/s00221-013-3667-1.
50. Deacon RM, Altimiras FJ, Bazan-Leon EA, Pyarasani RD, Nachtigall FM, Santos
LS, Tsolaki AG, Pednekar L, Kishore U, Biekofsky RR, Vasquez RA, Cogram P.
Natural AD-Like Neuropathology in Octodon degus: Impaired Burrowing
and Neuroinflammation. Curr Alzheimer Res. 2015;12(4):314–22.
51. Li Q, Zhao HF, Zhang ZF, Liu ZG, Pei XR, Wang JB, Cai MY, Li Y. Long-term
administration of green tea catechins prevents age-related spatial learning
and memory decline in C57BL/6 J mice by regulating hippocampal cyclic
amp-response element binding protein signaling cascade. Neuroscience.
2009;159(4):1208–15. doi:10.1016/j.neuroscience.2009.02.008.
52. Palmeri A, Privitera L, Giunta S, Loreto C, Puzzo D. Inhibition of
phosphodiesterase-5 rescues age-related impairment of synaptic plasticity
and memory. Behav Brain Res. 2013;240:11–20. doi:10.1016/j.bbr.2012.10.060.
53. Puzzo D, Bizzoca A, Loreto C, Guida CA, Gulisano W, Frasca G, Bellomo M,
Castorina S, Gennarini G, Palmeri A. Role of F3/contactin expression profile
in synaptic plasticity and memory in aged mice. Neurobiol Aging. 2015;
36(4):1702–15. doi:10.1016/j.neurobiolaging.2015.01.004.
54. He P, Cheng X, Staufenbiel M, Li R, Shen Y. Long-term treatment of
thalidomide ameliorates amyloid-like pathology through inhibition of beta-
secretase in a mouse model of Alzheimer's disease. PLoS One. 2013;8(2):
e55091. doi:10.1371/journal.pone.0055091.
55. Pype S, Moechars D, Dillen L, Mercken M. Characterization of amyloid beta
peptides from brain extracts of transgenic mice overexpressing the London
mutant of human amyloid precursor protein. J Neurochem. 2003;84(3):602–9.
56. Toda T, Noda Y, Ito G, Maeda M, Shimizu T. Presenilin-2 mutation causes
early amyloid accumulation and memory impairment in a transgenic mouse
model of Alzheimer's disease. J Biomed Biotechnol. 2011;2011:617974. doi:
10.1155/2011/617974.
57. Parkinson J, Ploeger B, Appelkvist P, Bogstedt A, Dillner Bergstedt K, Eketjall
S, Visser SA. Modeling of age-dependent amyloid accumulation and
gamma-secretase inhibition of soluble and insoluble Abeta in a transgenic
mouse model of amyloid deposition. Pharmacol Res Perspect. 2013;1(2):
e00012. doi:10.1002/prp2.12.
58. Krauthausen M, Kummer MP, Zimmermann J, Reyes-Irisarri E, Terwel D, Bulic
B, Heneka MT, Muller M. CXCR3 promotes plaque formation and behavioral
deficits in an Alzheimer's disease model. J Clin Invest. 2015;125(1):365–78.
doi:10.1172/JCI66771.
59. Beach TG, Kuo YM, Schwab C, Walker DG, Roher AE. Reduction of cortical
amyloid beta levels in guinea pig brain after systemic administration of
physostigmine. Neurosci Lett. 2001;310(1):21–4.
Steffen et al. Acta Neuropathologica Communications  (2016) 4:91 Page 11 of 11
